PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. reported a net loss of $77.7 million for FY 2025, an increase from a net loss of $58.7 million in FY 2024. The company generated no revenue, consistent with prior periods, as it remains a clinical-stage precision oncology company focused on developing p53-targeted therapies. Total operating expenses were $86.2 million, driven primarily by a $69.9 million investment in research and development, which increased by $11.4 million year-over-year due to advancing its lead candidate, rezatapopt, through Phase 2 clinical trials. This was partially offset by a $10.6 million decrease in general and administrative expenses. The company ended the year with $112.9 million in cash, cash equivalents, and marketable securities, which it estimates will fund operations until the end of Q2 2027. A key forward-looking event is the planned submission of a New Drug Application for rezatapopt in Q1 2027.

Key Takeaways